Multimedia

Masterclasses in Dermatology Co-Chair Dr Joseph Merola chats with Dr Katharina Shaw, SVP, Dermatology Franchise, Priovant Therapeutics, about the recent FDA approval of Lisraya as the first oral therapy for adult dermatomyositis.

Dr Raj Chovatiya explains how type 2 inflammation drives mast cell activation in chronic spontaneous urticaria (CSU), highlighting the roles of IL-4, IL-13, and IgE in both immune and neuroimmune pathways.

Shared decision-making in alopecia areata is often more complex than it appears. Dr Oyetewa Asempa discusses aligning treatment goals, managing expectations, and improving patient-clinician communication.

Hair regrowth is only one measure of success in alopecia areata. Dr Zoe Draelos highlights patient-centered outcomes, quality of life, emotional well-being, and long-term disease control.

Treating alopecia areata extends beyond managing hair loss. Dr Oyetewa Asempa explores gaps in psychosocial care, patient communication, and integrating mental health into clinical practice.

Successful alopecia areata treatment doesn't always mean therapy should end. Dr Emma Guttman discusses relapse risk, maintenance strategies, and setting realistic expectations for long-term disease management.

Complete hair loss doesn't necessarily mean treatment failure in alopecia areata. Examine the latest evidence on therapeutic response, severe disease, and evolving treatment strategies.